Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Vinorelbine with Filgrastim in Advanced NSCLC
NCT00006215Phase 2Unknown
- Sponsor
- Amgen
- Start
- Oct 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and vinorelbine in non-small cell lung cancer (NSCLC), sponsored by Amgen. Primary endpoint: Response to docetaxel and vinorelbine. Status: unknown.
02
Drugs
docetaxelvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00006215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006215.